再発および/または難治性B細胞悪性腫瘍におけるPIT565の研究
再発および/または難治性B細胞悪性腫瘍患者におけるPIT565の第I相非盲検多施設試験
This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is an open-label, multicenter, phase I study of PIT565 in patients with R/R B-NHL and R/R B-ALL.
The study comprises a dose escalation part of PIT565 in two independent groups (group A: R/R B-NHL and B: R/R B-ALL) and a dose expansion part in three independent groups (R/R large B-cell lymphoma (LBCL) randomized in 1:1 ratio to two RDs (A1 and A2), and R/R B-ALL (B1)).
During the dose escalation, the safety (including the dose-dose limiting toxicity (DLT) relationship) and tolerability of PIT565 will be assessed, and schedule(s), route(s) of administration and dose(s) will be identified for use in the expansion part based on the review of these data. The RD will also be guided by the available information on pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity. The dose escalation will be guided by an adaptive Bayesian logistic regression model (BLRM) following the Escalation with Overdose Control (EWOC) principle.
Different schedules and routes of administrations will be explored in the dose escalation groups.
The dose expansion will further explore the MTD(s) and/or RD(s) and the selected schedule(s) and route of administration(s) in the three patients' groups.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Florida
-
Miami、Florida、アメリカ、33136
- University Of Miami
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- University of Chicago Medical Center
-
-
Kansas
-
Fairway、Kansas、アメリカ、66205
- The University of Kansas Clinical Research Ctr
-
-
New York
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Ctr
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- Oregon Health Sciences University
-
-
-
-
-
Tel Aviv、イスラエル、6423906
- Novartis Investigative Site
-
-
-
-
RE
-
Reggio Emilia、RE、イタリア、42123
- Novartis Investigative Site
-
-
-
-
-
Singapore、シンガポール、119074
- Novartis Investigative Site
-
Singapore、シンガポール、169608
- Novartis Investigative Site
-
-
-
-
-
Barcelona、スペイン、08035
- Novartis Investigative Site
-
Barcelona、スペイン、08036
- Novartis Investigative Site
-
-
-
-
-
Créteil、フランス、94010
- Novartis Investigative Site
-
Marseille、フランス、13273
- Novartis Investigative Site
-
-
-
-
-
Ghent、ベルギー、9000
- Novartis Investigative Site
-
-
-
-
-
Beijing、中国、100730
- Novartis Investigative Site
-
Shanghai、中国、200032
- Novartis Investigative Site
-
Tianjin、中国、300020
- Novartis Investigative Site
-
-
-
-
Chiba
-
Kashiwa、Chiba、日本、2778577
- Novartis Investigative Site
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Signed informed consent must be obtained prior to participation in the study.
- Male or female patients ≥18 years of age at the date of signing the informed consent form
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2
NHL patient population
- Refractory or relapsed B-NHL
- Must have relapsed after or failed to respond to at least two prior treatment therapies including an αCD20 monoclonal antibody containing chemotherapy combination regimen
- Must have at least one bi-dimensionally measurable nodal lesion or one bi-dimensionally measurable extranodal lesion, as measured on positron emission tomography-computed tomography (PET/CT) scan
ALL patient population
- Refractory or relapsed CD19-positive B-ALL
- Morphologic disease in the bone marrow (≥ 5% blasts)
Exclusion Criteria:
- History of severe hypersensitivity to any ingredient of the study treatment or its excipients
- Contraindication to tocilizumab
- History of ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection
- Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type
- Active central nervous system (CNS) involvement by malignancy or presence of symptomatic CNS metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery), or increasing doses of corticosteroids within the 2 weeks prior to the start of study treatment
- Active, known or suspected autoimmune disease other than patients with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur
- Patients receiving systemic treatment with any immunosuppressive medication
Other protocol-defined inclusion/exclusion criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:PIT565 Group A (dose escalation part)
PIT565 in adult NHL patients for whom two or more lines of chemotherapy have failed and either having progressed (or relapsed) after autologous hematopoietic stem cell transplantation (HSCT), or being ineligible for or not consenting to the procedure |
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection |
|
実験的:PIT565 Group B (dose escalation part)
PIT565 in adult R/R ALL patients. |
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection |
|
実験的:PIT565 Group A1 (dose expansion part)
PIT565 Recommended dose 1 (RD1) in adult R/R large B-cell lymphoma (LBCL) (DLBCL, double/triple hit High-grade B-cell lymphoma (HGBCL), Primary mediastinal large B-cell lymphoma (PMBCL), Follicular lymphoma grade 3B (FL3B)) patients. |
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection |
|
実験的:PIT565 Group A2 (dose expansion part)
PIT565 RD2 in adult R/R LBCL (DLBCL, double/triple hit HGBCL, PMBCL, FL3B) patients. |
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection |
|
実験的:PIT565 Group B1 (dose expansion part)
PIT565 in adult R/R ALL patients. |
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence and severity of Dose Limiting Toxicities (DLTs)
時間枠:28 days or 35 days, depending on the dosing schedule
|
Assessment of safety of study drug. A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of CTCAE grade 3 or higher that occurs within the DLT evaluation period (28 days or 35 days depending on the schedule) and that is not primarily related to disease, disease progression, intercurrent illness, or concomitant medications with exceptions provided in the clinical protocol. |
28 days or 35 days, depending on the dosing schedule
|
|
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
時間枠:21 months
|
Assessment of safety of study drug. |
21 months
|
|
Frequency of dose interruptions
時間枠:21 months
|
Assessment of tolerability of study drug |
21 months
|
|
Frequency of dose reductions
時間枠:21 months
|
Assessment of tolerability of study drug |
21 months
|
|
Dose intensities
時間枠:21 months
|
Assessment of tolerability of study drug Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of exposure. |
21 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Response Rate (ORR)
時間枠:21 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Complete Response (CR) rate
時間枠:21 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Best Overall Response (BOR)
時間枠:21 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Duration Of Response (DOR)
時間枠:21 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Overall Survival (OS)
時間枠:33 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
33 months
|
|
Progression Free Survival (PFS)
時間枠:21 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Event-free survival (EFS)
時間枠:21 months
|
Evaluation of anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Maximum concentration of PIT565 (Cmax)
時間枠:21 months
|
Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s) |
21 months
|
|
Area Under the Curve of PIT565 (AUC)
時間枠:21 months
|
Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s) |
21 months
|
|
Trough concentration of PIT565 (C trough)
時間枠:21 months
|
Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s) |
21 months
|
|
Prevalence of Anti-drug antibodies (ADA) at baseline
時間枠:Baseline
|
Assessment of anti-PIT565 antibodies in serum. |
Baseline
|
|
Incidence of Anti-drug antibodies (ADA) on treatment
時間枠:21 months
|
Assessment of anti-PIT565 antibodies in serum. |
21 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- CPIT565A12101
- 2022-000367-45 (EudraCT番号)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。